Posters
Analysis of Primary and Secondary Ewing Sarcoma Outcomes
Presentation Type
Poster
Discipline Track
Other
Abstract Type
Research/Clinical
Abstract
Background: Ewing Sarcoma (EWS) is a rare cancer of bone and soft tissue that predominately occurs in adolescents and young adults. EWS is often associated with a second malignancy, which can occur before or after the EWS diagnosis. EWS occurring after a prior malignancy is less common and understudied. We aimed to determine whether clinical presentations and long-term survival were different between primary and secondary EWS.
Method: Patients diagnosed with EWS and confirmed by the EWSR-FLI1 fusion transcript by pathology reports at MD Anderson were analyzed by a retrospective chart review. Patients with a Peripheral Neuro-Ectodermal Tumor (PNET) diagnosis were not included in our cohort. Overall survival was determined by Kaplan-Meier methods and calculated using the log-rank test. Differences in average survival were calculated with two-sample t tests.
Results: Twenty-two cases of secondary EWS were reported, accounting for 47.8% of all EWS cases. Patients with secondary EWS were diagnosed with EWS at an older age than patients with primary EWS (47.9 years vs 30.6 years, p = 0.004). Patients with secondary EWS had a significantly lower five-year survival rate (16.7% vs 62.2%, p
Conclusion: Secondary EWS patients are diagnosed with EWS at an older age, have poorer long-term survival, take more time to develop a future malignancy, and respond worse to radiation therapy than primary EWS patients. These findings indicate that secondary EWS patients are distinct from primary EWS patients and possibly have a unique germline mutation predisposing them to EWS.
Recommended Citation
Kolodziej, Andrew and Lin, Patrick, "Analysis of Primary and Secondary Ewing Sarcoma Outcomes" (2023). Research Symposium. 115.
https://scholarworks.utrgv.edu/somrs/2022/posters/115
Analysis of Primary and Secondary Ewing Sarcoma Outcomes
Background: Ewing Sarcoma (EWS) is a rare cancer of bone and soft tissue that predominately occurs in adolescents and young adults. EWS is often associated with a second malignancy, which can occur before or after the EWS diagnosis. EWS occurring after a prior malignancy is less common and understudied. We aimed to determine whether clinical presentations and long-term survival were different between primary and secondary EWS.
Method: Patients diagnosed with EWS and confirmed by the EWSR-FLI1 fusion transcript by pathology reports at MD Anderson were analyzed by a retrospective chart review. Patients with a Peripheral Neuro-Ectodermal Tumor (PNET) diagnosis were not included in our cohort. Overall survival was determined by Kaplan-Meier methods and calculated using the log-rank test. Differences in average survival were calculated with two-sample t tests.
Results: Twenty-two cases of secondary EWS were reported, accounting for 47.8% of all EWS cases. Patients with secondary EWS were diagnosed with EWS at an older age than patients with primary EWS (47.9 years vs 30.6 years, p = 0.004). Patients with secondary EWS had a significantly lower five-year survival rate (16.7% vs 62.2%, p
Conclusion: Secondary EWS patients are diagnosed with EWS at an older age, have poorer long-term survival, take more time to develop a future malignancy, and respond worse to radiation therapy than primary EWS patients. These findings indicate that secondary EWS patients are distinct from primary EWS patients and possibly have a unique germline mutation predisposing them to EWS.